TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36493603

Group type: EXPERIMENTAL
Intervention: Self-assessment using a tablet application for detecting herb and food-drug interactions (HFDIs).
Number of subjects: 143
Study: 36494591

Group type: EXPERIMENTAL
Intervention: Solriamfetol 150 mg/day (3 days) followed by 300 mg/day (4 days)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Solriamfetol
Number of subjects: 51

Group type: COMPARATOR
Intervention: Solriamfetol and Placebo
Number of subjects: 51
Study: 36494725

Group type: EXPERIMENTAL
Intervention: KTE-X19 (1 × 10^6 CAR T cells)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Matched historical controls (SCHOLAR-3)
Number of subjects: 55
Study: 36494743

Group type: EXPERIMENTAL
Intervention: Low-titre Group O whole blood (LTOWB)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Packed red blood cells (PRBC)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Freeze-dried plasma
Number of subjects: 52
Study: 36494748

Group type: EXPERIMENTAL
Intervention: Emotional Resilience Skills Training (ERST) tailored for diverse PSP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ongoing evidence-based assessments (annual, monthly, daily)
Number of subjects: 0
Study: 36494776

Group type: EXPERIMENTAL
Intervention: Multimodal diagnostic assessments including behavioral scales, quantitative electroencephalography, transcranial magnetic stimulation with electroencephalography, structural and resting-state functional MRI, and physiological activity measurements.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assessments of caregivers' well-being and treatment decision attitudes.
Number of subjects: 0
Study: 36494840

Group type: EXPERIMENTAL
Intervention: Cook Like A Boss Online intervention
Number of subjects: 248
Study: 36494874

Group type: EXPERIMENTAL
Intervention: Brainstem raphe hypoechogenicity (BRH) identified by transcranial sonography (TCS)
Number of subjects: 100
Study: 36495395

Group type: EXPERIMENTAL
Intervention: Phenotype B (subclinical macular edema with decreased vessel density < 2 SD of healthy controls)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Phenotype C (decreased vessel density ≥ 2 SD of healthy controls)
Number of subjects: 122
Study: 36495795

Group type: EXPERIMENTAL
Intervention: Reminiscence music therapy (60-minute sessions, twice a week for 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study: 36495927

Group type: EXPERIMENTAL
Intervention: Blood-based multi-cancer early detection (MCED) test
Number of subjects: 4077
Study: 36496135

Group type: EXPERIMENTAL
Intervention: Leadless pacemaker implantation following transvenous lead extraction (TLE)
Number of subjects: 1179

Group type: COMPARATOR
Intervention: De novo leadless pacemaker implantation
Number of subjects: 1179

Group type: EXPERIMENTAL
Intervention: Leadless pacemaker implantation at a different right ventricular (RV) location than previous transvenous RV lead extraction
Number of subjects: 1179
Study: 36496395

Group type: EXPERIMENTAL
Intervention: Pneumococcal DNA detection in nasopharynx
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Pneumococcal concentration (Ct value)
Number of subjects: 677

Group type: COMPARATOR
Intervention: Presence of serotype 19F
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Serotypes associated with radiological pneumonia
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Serotypes included in PCV13 vaccine
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Infections with multiple serotypes
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: PCR-determined concentrations of pneumococci
Number of subjects: 677
Study: 36496547

Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 187

Group type: COMPARATOR
Intervention: Other Tx
Number of subjects: 187
Study: 36497620

Group type: EXPERIMENTAL
Intervention: Moderate-Vigorous Physical Activity (PA)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (CRF)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Body composition changes
Number of subjects: 105
Study: 36497976

Group type: EXPERIMENTAL
Intervention: Osteoarticular cluster
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Minor chronic disease cluster
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Psychogeriatric cluster
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory cluster
Number of subjects: 740
Study: 36498758

Group type: EXPERIMENTAL
Intervention: Fu's subcutaneous needling (FSN)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 32
Study: 36498818

Group type: EXPERIMENTAL
Intervention: Anti-IL-17C monoclonal antibody MOR106, administered for up to 12 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified, but implied as standard treatment or placebo.
Number of subjects: 0
Study: 36499023

Group type: EXPERIMENTAL
Intervention: Insulin-induced hypoglycemia (2 mmol/L; 36 mg/dL)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no hypoglycemia)
Number of subjects: 46
Study: 36499525

Group type: EXPERIMENTAL
Intervention: IPAF group
Number of subjects: 40

Group type: COMPARATOR
Intervention: CTD-ILD group
Number of subjects: 40
Study: 36501072

Group type: EXPERIMENTAL
Intervention: 1−2 drinks/day (~12−24 g)
Number of subjects: 26
Study: 36501177

Group type: EXPERIMENTAL
Intervention: Real-Life exercise intervention
Number of subjects: 50
Study: 36502794

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen
Number of subjects: 95

Group type: COMPARATOR
Intervention: Intravenous (IV) ibuprofen
Number of subjects: 95
Study: 36503177

Group type: COMPARATOR
Intervention: RPM-conventional
Number of subjects: 1339

Group type: COMPARATOR
Intervention: RPM-alert
Number of subjects: 1339
Study: 36503252

Group type: EXPERIMENTAL
Intervention: Lipoprotein(a) [Lp(a)] levels
Number of subjects: 377
Study: 36503279

Group type: EXPERIMENTAL
Intervention: EMS-treated OHCAs
Number of subjects: 92913
Study: 36503310

Group type: EXPERIMENTAL
Intervention: Milano-Torino staging (MiToS)
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: King's staging
Number of subjects: 456
Study: 36503413

Group type: EXPERIMENTAL
Intervention: Low-dose aerosolised Ad5-nCoV
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: High-dose aerosolised Ad5-nCoV
Number of subjects: 419

Group type: COMPARATOR
Intervention: CoronaVac (control group)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 419
Study: 36503429

Group type: EXPERIMENTAL
Intervention: MDT alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MDT with 1 month ADT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MDT with 6 months ADT and ARTA (enzalutamide 4×40 mg daily for 6 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MDT
Number of subjects: 0
Study: 36503495

Group type: EXPERIMENTAL
Intervention: mtFIT
Number of subjects: 13131

Group type: COMPARATOR
Intervention: FIT
Number of subjects: 13131
Study: 36503500

Group type: EXPERIMENTAL
Intervention: Pressure support with positive end-expiratory pressure
Number of subjects: 0

Group type: COMPARATOR
Intervention: T-piece
Number of subjects: 0
Study: 36503505

Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Conventional Wound Treatment (CWT)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Outpatient NPWT
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Outpatient CWT after NPWT
Number of subjects: 157
Study: 36503610

Group type: EXPERIMENTAL
Intervention: Nivolumab (PD-1 inhibitor) followed by SBRT (30 Gy in 3 to 5 fractions)
Number of subjects: 40
Study: 36503690

Group type: EXPERIMENTAL
Intervention: Registry-based identification and invitation for ultrasound examination of first-degree relatives to AAA patients.
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Control group without hereditary risk for AAA.
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Evaluation of anxiety for disease and health-related quality of life (HRQoL).
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of the study.
Number of subjects: 1500
Study: 36503736

Group type: EXPERIMENTAL
Intervention: OCS-01 once daily
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: OCS-01 BID
Number of subjects: 153

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 153
Study: 36503738

Group type: EXPERIMENTAL
Intervention: Napabucasin plus FOLFIRI
Number of subjects: 1253

Group type: COMPARATOR
Intervention: FOLFIRI alone (control)
Number of subjects: 1253
Study: 36504158

Group type: EXPERIMENTAL
Intervention: Fesoterodine 4 mg and 8 mg extended-release tablets
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Fesoterodine 2 mg and 4 mg extended-release beads-in-capsule (BIC)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Fesoterodine 4 mg and 8 mg extended-release tablets and 4 mg BIC
Number of subjects: 181

Group type: COMPARATOR
Intervention: Oxybutynin XL tablets
Number of subjects: 181
Study: 36504254

Group type: EXPERIMENTAL
Intervention: CST-PM microbiome (polymicrobial)
Number of subjects: 688

Group type: COMPARATOR
Intervention: CST-LC microbiome (Lactobacillus crispatus)
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: CST-PM microbiome (polymicrobial) in women aged 20-24 years
Number of subjects: 688

Group type: COMPARATOR
Intervention: CST-LI microbiome (Lactobacillus iners)
Number of subjects: 688

Group type: COMPARATOR
Intervention: CST-GV microbiome (Gardnerella vaginalis)
Number of subjects: 688
Study: 36504291

Group type: EXPERIMENTAL
Intervention: Verinurad 24 mg extended release with allopurinol 300 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Verinurad 40 mg immediate release with allopurinol 300 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Matching placebos
Number of subjects: 24
Study: 36504759

Group type: EXPERIMENTAL
Intervention: Psychological trauma assessment in FM patients
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Traumatic events prior to the onset of pain
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Clinical symptoms assessment
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Pain levels
Number of subjects: 88
Study: 36505277

Group type: EXPERIMENTAL
Intervention: targeted high-throughput next-gen sequencing (tNGS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: traditional culture-based approach
Number of subjects: 20
Study: 36505379

Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (PVI)
Number of subjects: 1576

Group type: COMPARATOR
Intervention: No PVI
Number of subjects: 1576
Study: 36505793

Group type: EXPERIMENTAL
Intervention: Vemurafenib with pembrolizumab
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Triple therapy (vemurafenib, cobimetinib, and pembrolizumab)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Quality of Life assessments
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Adverse Events
Number of subjects: 9
Study: 36505833

Group type: EXPERIMENTAL
Intervention: Lenvatinib 8-12mg once daily and sintilimab 200mg once every three weeks combined with radiotherapy (3Gy*10 fraction)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lenvatinib and sintilimab combined with radiotherapy
Number of subjects: 20
Study: 36505849

Group type: EXPERIMENTAL
Intervention: Fruquintinib
Number of subjects: 128

Group type: COMPARATOR
Intervention: Other TKIs
Number of subjects: 128
Study: 36505885

Group type: EXPERIMENTAL
Intervention: High-dose luspatercept (0.6-1.25 mg/kg) for NTD patients
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: High-dose luspatercept (0.6-1.25 mg/kg) for TD patients
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: High-dose luspatercept (0.6-1.25 mg/kg)
Number of subjects: 64
Study: 36506070

Group type: EXPERIMENTAL
Intervention: Sclerostin
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: DKK-1
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Sclerostin and DKK-1 ratio
Number of subjects: 39
Study: 36506077

Group type: EXPERIMENTAL
Intervention: FGM use with remote intervention
Number of subjects: 36

Group type: COMPARATOR
Intervention: FGM use only (control group)
Number of subjects: 36
Study: 36506445

Group type: EXPERIMENTAL
Intervention: Web-based educational information
Number of subjects: 325

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 325
Study: 36506562

Group type: EXPERIMENTAL
Intervention: SHR7280, an oral gonadotropin-releasing hormone antagonist
Number of subjects: 0
Study: 36506749

Group type: EXPERIMENTAL
Intervention: tofacitinib 10 mg BID
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: tofacitinib 5 mg BID
Number of subjects: 0
Study: 36506775

Group type: EXPERIMENTAL
Intervention: 0.03 mg/kg midazolam
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg midazolam
Number of subjects: 312

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 312
Study: 36507576

Group type: EXPERIMENTAL
Intervention: Tezepelumab 210 mg subcutaneously every 4 weeks for 52 weeks
Number of subjects: 1059

Group type: EXPERIMENTAL
Intervention: Tezepelumab
Number of subjects: 1059

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1059
Study: 36507677

Group type: EXPERIMENTAL
Intervention: Telacebec (Q203) at doses of 20, 50, 100, 160, 250, and 320 mg, orally administered once daily for 14 days
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 36507686

Group type: EXPERIMENTAL
Intervention: Talquetamab (405 μg per kilogram weekly)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Talquetamab (800 μg per kilogram every other week)
Number of subjects: 232
Study: 36507690

Group type: EXPERIMENTAL
Intervention: Glofitamab monotherapy (12 cycles total) after pretreatment with obinutuzumab
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Glofitamab monotherapy
Number of subjects: 155
Study: 36507736

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 2267
Study: 36507738

Group type: EXPERIMENTAL
Intervention: 15 mg psilocybin
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: 25 mg psilocybin
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: 30 mg psilocybin
Number of subjects: 79
Study: 36507781

Group type: EXPERIMENTAL
Intervention: Integrated boost to the dominant intraprostatic nodule in stereotactic body radiation therapy, details on dosage and duration not available.
Number of subjects: 0
Study: 36507973

Group type: EXPERIMENTAL
Intervention: lonafarnib
Number of subjects: 2

Group type: COMPARATOR
Intervention: untreated cohort
Number of subjects: 2
Study: 36508217

Group type: EXPERIMENTAL
Intervention: Multisectoral agriculture and livelihood intervention (loan for irrigation pump, fertilizer, seeds, pesticides, training in sustainable agriculture and financial literacy)
Number of subjects: 720

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Multisectoral agriculture and livelihood intervention
Number of subjects: 720

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 720
Study: 36508251

Group type: EXPERIMENTAL
Intervention: Physiorehabilitation with Virtual Reality (VR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard physiotherapy (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physiorehabilitation with VR
Number of subjects: 0
Study: 36508302

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxorubicin, Vinblastine, and Dacarbazine (ABVD)
Number of subjects: 0
Study: 36508390

Group type: EXPERIMENTAL
Intervention: Neurofilament light chain (NfL)
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Progranulin
Number of subjects: 475
Study: 36508644

Group type: EXPERIMENTAL
Intervention: Molecular Microscope Diagnostic System (MMDx)
Number of subjects: 0
Study: 36508732

Group type: EXPERIMENTAL
Intervention: Empathy appeal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deontological appeal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Identifiable victim appeal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reciprocity appeal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no appeal)
Number of subjects: 0
Study: 36508737

Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate, High-Fat (LCHF) diet
Number of subjects: 165

Group type: COMPARATOR
Intervention: High-Carbohydrate, Low-Fat (HCLF) diet
Number of subjects: 165
Study: 36509053

Group type: EXPERIMENTAL
Intervention: Azithromycin (single-dose)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Amoxicillin (7-day course, standard of care)
Number of subjects: 301
Study: 36509063

Group type: EXPERIMENTAL
Intervention: MMV390048 (120 mg)
Number of subjects: 8
Study: 36509097

Group type: EXPERIMENTAL
Intervention: Rocatinlimab 150 mg every 4 weeks
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Rocatinlimab 600 mg every 4 weeks
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Rocatinlimab 300 mg every 2 weeks
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Rocatinlimab 600 mg every 2 weeks
Number of subjects: 274

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study: 36509100

Group type: EXPERIMENTAL
Intervention: RO7020531 (doses: 3 mg, 10 mg, 20 mg, 40 mg, 60 mg, 100 mg, 140 mg, 170 mg)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: RO7020531 (150 mg, 170 mg)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: RO7020531 (150 mg)
Number of subjects: 450
Study: 36509112

Group type: EXPERIMENTAL
Intervention: Opioid users
Number of subjects: 89

Group type: COMPARATOR
Intervention: Nonusers
Number of subjects: 89

Group type: COMPARATOR
Intervention: Both groups (Opioid users and Nonusers)
Number of subjects: 89
Study: 36509113

Group type: EXPERIMENTAL
Intervention: Contrast guidance
Number of subjects: 118

Group type: COMPARATOR
Intervention: Fanning technique
Number of subjects: 118
Study: 36509248

Group type: EXPERIMENTAL
Intervention: Super Enhanced Single Vision Lens 01 (SESL01)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard single vision lenses
Number of subjects: 300
Study: 36509249

Group type: EXPERIMENTAL
Intervention: SB with once/h 5 min walk break
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: SB with once/h 15 min stand break
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: SB with twice/h breaks (alternating 5 min walk and 15 min stand)
Number of subjects: 56

Group type: COMPARATOR
Intervention: SB with no breaks (control)
Number of subjects: 56
Study: 36509366

Group type: EXPERIMENTAL
Intervention: Cystic Fibrosis Questionnaire-Revised (CFQ-R)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Time trade-off (TTO) exercise
Number of subjects: 400
Study: 36509407

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks for 24 weeks (VENTURE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dupilumab (TRAVERSE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dupilumab (VENTURE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (VENTURE)
Number of subjects: 0
Study: 36509812

Group type: EXPERIMENTAL
Intervention: PCT, IL-6, IP-10
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Clinical variables combinations
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: CD74
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Cord blood PCT
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: CD74 with IP-10 or clinical criterion
Number of subjects: 581
Study: 36510180

Group type: EXPERIMENTAL
Intervention: Intensive educational intervention maintained over two years (n=51)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Only initial education (n=49)
Number of subjects: 100
Study: 36510181

Group type: EXPERIMENTAL
Intervention: MyPlan 2.0 digital health intervention
Number of subjects: 65
Study: 36510222

Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent donors (CCD)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Perturbed CCD samples (n=21)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Cluster P1 (n=8) CCD samples
Number of subjects: 162
Study: 36510234

Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis protocol (mechanical, pharmacological, or combined)
Number of subjects: 884

Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis protocol
Number of subjects: 884
Study: 36510233

Group type: EXPERIMENTAL
Intervention: SPIN-HAND Program (internet-based self-guided hand exercise program)
Number of subjects: 466

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 466
Study: 36510237

Group type: EXPERIMENTAL
Intervention: escitalopram
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: nortriptyline
Number of subjects: 408

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 408
Study: 36510271

Group type: EXPERIMENTAL
Intervention: Ropivacaine plus D-PAL emulsion
Number of subjects: 130

Group type: COMPARATOR
Intervention: Ropivacaine alone
Number of subjects: 130
Study: 36510290

Group type: EXPERIMENTAL
Intervention: Remimazolam tosylate at 0.15 mg/kg
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Remimazolam tosylate at 0.2 mg/kg
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Propofol at 1.5 mg/kg
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1800
Study: 36510319

Group type: EXPERIMENTAL
Intervention: weCare/Secure intervention
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Food-secure PWH
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Food-insecure PWH
Number of subjects: 1800
Study: 36510324

Group type: EXPERIMENTAL
Intervention: Ultra-lung-protective ventilation (1-2 mL/kg tidal volume, 5-10 cycles per minute, positive expiratory transpulmonary pressure, 16 hours of prone position)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Lung-protective ventilation (control group, following EOLIA trial protocol)
Number of subjects: 39
Study: 36510345

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Buccal misoprostol
Number of subjects: 124